Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Outstanding (Weighted Average) (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Shares Outstanding (Weighted Average) over the past 12 years, most recently at $84.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $84.8 million for Q4 2025, up 34056.75% from a year ago — trailing twelve months through Dec 2025 was $84.8 million (up 34056.75% YoY), and the annual figure for FY2025 was $84.8 million, up 34056.75%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $84.8 million at Viridian Therapeutics, Inc.\DE, up from $134864.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for VRDN hit a ceiling of $84.8 million in Q4 2025 and a floor of $66385.0 in Q4 2023.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $374047.0 (2021), compared with a mean of $15.1 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 34056.75% in 2025, while the deepest fall reached 99.8% in 2025.
  • Viridian Therapeutics, Inc.\DE's Shares Outstanding (Weighted Average) stood at $11.9 million in 2021, then tumbled by 98.3% to $203190.0 in 2022, then plummeted by 67.33% to $66385.0 in 2023, then soared by 274.0% to $248277.0 in 2024, then soared by 34056.75% to $84.8 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $84.8 million (Q4 2025), $134864.0 (Q3 2025), and $134864.0 (Q2 2025) per Business Quant data.